// App-Quantinova.ai

: Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial

Researchers

Presenter

  • J.M.S.Bartlett

Principal Investigators

  • D.C.Sgroi

  • K.Treuner

  • Y.Zhang

  • I.Ahmed

  • T.Piper

  • R.Salunga

  • E.F.Brachtel

  • S.J.Pirrie

  • C.A.Schnabel

  • D.W.Rea

Medical Centers

  • Ontario Institute for Cancer Research, Toronto, ON, Canada

  • University of Edinburgh Cancer Research Centre, Edinburgh, UK

  • Department of Pathology, Massachusetts General Hospital, Boston, MA

  • Biotheranostics Inc., San Diego, USA

  • Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK

Locations

  • Canada

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Progesterone receptor

Drug/Treatment

  • Tamoxifen

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • ISRCTN17222211

  • NCT00003678

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved